Back to Archived News
Lakewood-Amedex Inc. Receives Notice of Allowance on Three US Patent Applications Relating to Treatment of Hemolytic Uremic Syndrome
Thursday, January 27, 2011
Sarasota, FL -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that the United States Patent and Trademark Office has issued Notice of Allowances on three patent applications relating to the use of novel monoclonal antibodies for the treatment of hemolytic uremic syndrome (HUS) caused by shiga toxin II secreting E.coli O157: H7 strain.
Lakewood Amedex is the exclusive licensee of the US patents, issued to Tufts University. Based on work led by Saul Tzipori, BVSc., DSc., PhD, distinguished professor of biomedical sciences at the Cummings School of Veterinary Medicine at Tufts, as well as other members of the school's Division of Infectious Diseases, the patents entitled -- "Humanized Neutralizing Antibodies against Hemolytic Uremic Syndrome" -- are the first patents to be granted in this family and will provide the Company with a strong intellectual property position for treating this serious illness. HUS is usually associated with E.coli0157:H7 food poisoning and affects more than 300,000 people worldwide annually. There is currently no approved therapeutics for the treatment of this condition, which mainly affects young children and the elderly, as well as individuals with compromised immune systems. The Company is seeking to fast-track development of its lead fully human monoclonal antibody candidate into clinical trials in 2011.
The Company's head scientist, Paul DiTullio, commented "The granting of these three patents will give Lakewood-Amedex a dominant position for the use of monoclonal antibodies to treat this life threatening condition. Although the initial indication will be for the treatment of hemolytic uremic syndrome, the Company believes the product will have a more expanded usage in preventing the kidney damage caused by shiga toxin in patients suffering from a less severe infection which can lead to a number of health complications later in life. The market for this product is estimated to be between $100 million and $400 million annually on a worldwide basis.
About Lakewood-Amedex, Inc.
Lakewood-Amedex is a privately held biopharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class anti-bacterial compounds, orally available nanoRNA therapeutics for acute and chronic diseases such as arthritis, inflammation, influenza, and hepatitis, and a fully human monoclonal antibody for HUS. The Company's products and technology are covered by an extensive patent portfolio consisting of 27 granted and/or issued patents and 32 pending patent applications filed on a worldwide basis covering all major pharmaceutical markets. The Company's lead therapeutic candidate is a novel synthetic broad spectrum anti-bacterial proven to be effective in killing a wide range of gram positive, gram negative, and antibiotic-resistant bacteria and is expected to enter the clinic in 2011.
This press release contains forward-looking statements that can be identified by terminology such as "expects", "potential", "suggests", "may", "will" or similar expressions. Such forward-looking statements regarding our business, which are not historical facts, are "forward-looking statements" that involve risk and uncertainties, which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. Actual results may differ materially from statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company's operations, risk associated with product research and development, and competition. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.
Back to Archived News